ArticleInternational journal of hematology2025
Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis.International journal of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inappropriate discontinuation of immunosuppressive drugs (ISD) following allogeneic hematopoietic cell transplantation (HCT) can lead to the development of chronic graft-versus-host disease (cGVHD) and necessitate the reintroduction of ISD. However, only a few studies have compared the discontinuation rates of secondary steroid for cGVHD between different stem cell sources. We retrospectively evaluated 191 patients who underwent HCT at our institution to determine the discontinuation rates of secondary steroids for cGVHD. 50 patients (26.7%) received secondary steroid for cGVHD. After additional steroid for cGVHD, the 2-year cumulative steroid discontinuation rates were 50.0%, 0%, 8.3%, 44.0%, and 40.0% for MSD, uPBSC, uBM, UCB, PTCy-haplo, respectively (P = 0.0313). Patients transplanted with uBM or uPBSC had significantly lower cumulative discontinuation rates of additional steroids for cGVHD compared to those transplanted with other stem cell sources (P < 0.001). Multivariate analysis indicated that the cumulative steroid discontinuation rate was significantly lower in uPBSC or uBM group compared to in MSD group (uPBSC, HR, 0.10; P = 0.024, uBM, HR, 0.13; P = 0.007). Therefore, careful steroid reduction or additional treatment for cGVHD is necessary in patients transplanted with uBM and uPBSC.
Indexed as
Identifiers
39585531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.